Biomarker to Begin Study of a New Blood Test for Breast Cancer

Biomarker Technologies, the worldwide technology provider of the blood diagnostic test for the detection of breast cancer called the BT Test, announced plans to begin a pilot study of the test in the U.S. beginning in April 2005. The company is conducting the pilot study to verify its prior results and make final preparations for FDA clinical studies. The study will be a retrospective blind test with samples from healthy participants, those with untreated breast cancer, as well as those from a select group of other cancer conditions in order to demonstrate the differentiation capabilities of the test.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050323005072&newsLang=en)